Quantcast
Last updated on April 24, 2014 at 21:24 EDT

Latest Long-term nonprogressor Stories

2014-01-24 11:34:18

Drug resistance mutations in HIV reduce the genetic diversity in the rest of the virus genome when they spread within an infected patient, but they do so to a different extent in different patients. A new study published in PLOS Genetics, by Dr Pleuni Pennings and colleagues, found that in some patients a resistance mutation to a particular drug appeared in a single virus particle, which then rapidly proliferated until the entire viral population within the patient consisted of its progeny...

Researchers Demonstrate 'Guided Missile' Strategy To Kill Hidden HIV
2014-01-10 13:59:06

University of North Carolina Health Care The finding provides a new route to killing persistent HIV-infected cells -- a major roadblock to a cure Researchers at the UNC School of Medicine have deployed a potential new weapon against HIV – a combination therapy that targets HIV-infected cells that standard therapies cannot kill. Using mouse models that have immune systems composed of human cells, researchers led by J. Victor Garcia, PhD, found that an antibody combined with a...

2013-11-26 13:47:08

Study proposes new benchmarks for clinical treatment of HIV People with human immunodeficiency virus (HIV) run a higher risk of virologic failure than previously thought, even when their number of RNA copies of the retrovirus per millilitre of blood is slightly above the detection threshold, according to a study by Claudie Laprise at the University of Montreal's Department of Social and Preventative Medicine. Her findings were published in Clinical Infectious Diseases. The study was...

2013-10-28 08:28:24

Reduction of Viral Load at or Below Limit of Detection Ongoing at 14 Weeks RICHMOND, Calif., Oct. 28, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of new data demonstrating sustained control of HIV viral load (VL) at or below the limit of detection for 14 weeks (at last measurement) in an SB-728-T- treated HIV-infected subject who was not on antiretroviral therapy (ART). The CCR5 delta-32 heterozygote subject is enrolled in Sangamo's...

First Ever Baby Cured Of HIV Still In Remission 18 Months Later
2013-10-24 07:28:39

Lawrence LeBlond for redOrbit.com - Your Universe Online An HIV case first documented in a Mississippi baby 18 months ago is still proving that an antiviral treatment early on is effective in not only treating the virus that causes AIDS, but also curing it. Earlier this year, researchers from Johns Hopkins University (JHU) reported that a child born with HIV and treated with a series of antiviral drugs showed signs of remission within days of initial treatment. The child was...

2013-09-12 16:27:49

Sustained Reduction of Viral Load at or Below Limit of Detection during Treatment Interruption of Antiretroviral Therapy RICHMOND, Calif., Sept. 12, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of new data from its ongoing Phase 2 clinical trial (SB-728-902 Cohort 5) to evaluate a single infusion of Sangamo's novel ZFP Therapeutic(®), SB-728-T, for the treatment of HIV/AIDS. The data demonstrate functional control of the virus at or below...

Two Boston Patients HIV Free After Bone Marrow Transplant
2013-07-03 11:32:32

Brett Smith for redOrbit.com - Your Universe Online After a series of grueling and risky treatments, two HIV-infected patients from Boston have tested negative for the virus after stopping their daily regimen of antiretroviral drugs, according to an announcement made at an international AIDS conference on Wednesday. Doctors credit the phenomenon to bone marrow transplants the patients received several years ago to treat advanced-stage blood cancer. "I don't want to use the 'cure'...

2013-06-19 12:12:26

Study among people with HIV People with HIV are more likely to keep their scheduled medical appointments – and their disease under control – if they feel their physician listens, explains things clearly and knows them as a person, not just a "case," new Johns Hopkins research suggests. "If people feel their doctor really knows them and listens to them, they feel that doctor has their best interests at heart and may be more likely to follow medical advice," says study leader...

2013-05-15 12:33:24

Unprecedented Immune Reconstitution Drives HIV Viral Reservoir Depletion RICHMOND, Calif., May 15, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of new clinical data from its program to develop a ZFP Therapeutic(®) for HIV/AIDS. The data, which demonstrate that SB-728-T treatment results in a reduction in the HIV reservoir in HIV-infected subjects, are being presented at the 16(th) Annual Meeting of the American Society of Gene...

2013-03-06 12:26:23

Data Demonstrate that SB-728-T Possesses Necessary Immunologic Properties to Support a 'Functional Cure' for HIV/AIDS RICHMOND, Calif., March 6, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced new data from its program to develop a 'functional cure' for HIV/AIDS in two presentations at the 20(th) Conference on Retroviruses and Opportunistic Infections (CROI), held in Atlanta from March 3 to 6, 2013. (Logo:...